Abveris Information
Contact top employees from
Abveris
Summary
Abveris is a private company that has been in the industry for 11 years. The company currently specializes in the Biotechnology, Biotechnology areas. The position of the CEO is occupied by Tracey Mullen. Its headquarters is located at Canton, Massachusetts, USA. The number of employees ranges from 25 to 100. The annual revenue of Abveris varies between 5.0M and 25M. To connect with Abveris employee register on SignalHire.
Organization Website | abveris.com |
Social Links |    |
Phone Number | 781-562-1170 |
Industries | |
Headquarters Location | 1250 Hancock St, Quincy, Massachusetts, 02169 US |
Employees Size | 100-200 employees |
Specialties | Antibody Discovery, Anti-Idiotype Antibodies, Hybridoma Discovery, Antibody Therapeutics, In Vivo Discovery, Reagent Antibodies |
DMA Code | Greater Boston |
Founded | 2014 |
Estimated Annual Revenue | $5.0M - 25M |
Operating Status | Independent Company |
Competitors
Founded | Type | Employees | Revenue | Funding | |
|---|---|---|---|---|---|
| 2008 | Privately Held | 1 - 25 | < 1M | $82.5M | |
| 2007 | Privately Held | 100 - 250 | 15M | $32.3M | |
| 2004 | Public Company | 100 - 250 | 6.5M | $610M | |
| 2006 | Privately Held | 25 - 100 | 10M | $0 |
Employees Turnover 3 quarter 2025
Length of Employment
Employee tenure at Abveris shows a diverse range of experience levels:
27% for 3–4 years53% for 5–7 years13% for 8–10 years7% have over 11 years of service at AbverisContact top employees from
Abveris
Chloe Emery
Vivarium Director
Shaun Josephs
Facilities Manager
Christine Ngo
Lab Manager
Similar Companies
FAQ
Abveris operates in the Biotech industries. More details can be found on the official website: abveris.com.
The headquarters of Abveris are located in Quincy, United States.
The current CEO of Abveris is Tracey Mullen
You can contact Abveris by phone at 781-562-1170.
Abveris currently employs 100-200 people.
Abveris's revenue is approximately 5.8M.
Well-known competitors of Abveris include Immunome, Inc., Adimab, Alder BioPharmaceuticals, Inc. and System Biosciences, a CellBio Scientific Company.
